Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain.
Visceral pain is the major cause of consulting in gastroenterology and the principal symptom of functional bowel disorders. This symptom is often associated with gut hypersensitivity to distension. The use of animal models has recently permitted the identification of some mediators supposed to play a pivotal role in the genesis of visceral hypersensitivity. Serotonin, through different receptor subtypes, as well as kinins and calcitonin gene-related peptide, are known to be involved, but other putative transmitters arise and are new potential targets for the development of efficacious treatments. This themes article addresses both physiological and preclinical issues of interest for the selection of active new drugs in regard to the clinical pharmacology of visceral pain.
Buéno
L
L
Institut National de la Recherche Agronomique, Neuro-Gastroenterology & Nutrition Unit, 31931 Toulouse, France. lbueno@toulouse.inra.fr
Fioramonti
J
J
Garcia-Villar
R
R
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D006930:Hyperalgesia / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology*; D017833:Visceral Afferents / Q000503:physiopathology*
D000700:Analgesics